Meline ID
The best way to treat combined melasma.
The Meline peel treats hyperpigmentation, but it also acts as a prevention of staining, unlike regular peels. The ID (Intradermal Injection) maximizes the efficacy of the overall treatment. The treatment lasts approximately 3 to 4 weeks and continues to work during the 2 to 3 months following your peel and it is at this time that you can notice the real result !

Meline ID
The best way to treat combined melasma.
The Meline peel treats hyperpigmentation, but it also acts as a prevention of staining, unlike regular peels. The ID (Intradermal Injection) maximizes the efficacy of the overall treatment. The treatment lasts approximately 3 to 4 weeks and continues to work during the 2 to 3 months following your peel and it is at this time that you can notice the real result !
Benefits of the Meline ID
Reduce mixed melasma
Epidermal melasma is the most superficial with an increase in the skin pigment (melanin) in the top layer of skin (epidermis). In dermal melasma, there is increased skin pigment in the second deeper layer of the skin (the dermis). Mixed melasma is a combination of epidermal and dermal melasma.
Reduce hyperpigmentation
Skin looks brighter and skin tone more even by 90-95% within 60-90 days
FAQs
What are the side effects?
Immediate (same day and over the next week following your peel) after effects include reddening and flaky skin. Peeling tends to start after 48 hours and will last for 3-4 days.
How many sessions are necessary?
Depending on the skin, 3 to 6 sessions once every month are necessary. However long-term results depend on regular use of SPF.
Are there contraindications?
Diabetes, pacemaker, immunosuppressants, blood thinning medication, pregnancy/breastfeeding, significant skin disease/infections (cold sores), history of Keloid scarring, tanning, active bacteria (viral, fungal, herpetic infection), open wounds, pre-existing inflammatory dermatoses (psoriasis, atopic dermatitis, pemphigus), facial cancers (melanoma), oral acne medication isotretinoin (Myorisan, Claravis, others) in the past six months.